Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

著者: Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Façon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al‐Ola Abdallah, Ashraf Badros, Stefan Knop, Edward A. Stadtmauer, Yiming Cheng, Michael Amatangelo, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Teresa Peluso, Niels W.C.J. van de Donk - The Lancet 2022 被引用: 92